What is the Market Cap of Lupin?

It indicates the value of the outstanding shares of a publicly traded firm. As of 25 Apr, 2024, Lupin's market cap stands at Rs 72664.80 crores.

Is Lupin part of Nifty 50?

Yes, Lupin belongs to the Nifty 50 index.

What is the dividend of Lupin in 2023?

In March 2023, Lupin declared an equity dividend of 200% with Rs 4 per share. The company's current share price provided a 0.25% dividend yield.

Is Lupin a debt-free company?

Lupin can be virtually considered debt-free, with a PEG ratio of 0.22 and a smooth conversion cycle of 65.84 days.

Is Lupin a good stock to buy?

Lupin seems like a good stock to buy on the basis of its current market price, future growth prospects, and profit margins. Moreover, the company has no threat of bankruptcy in the near future.

What is the future of Lupin Limited's shares?

Lupin Limited's shares are going to increase in value in the future as the company is focusing on enhanced patient care and drug development to generate fresh revenue streams.

What is Lupin Ltd Share symbol?

Lupin Ltd. has a share symbol of LUPIN.

Who is/are the promoter/promoters of Lupin Ltd?

The promoters of Lupin Ltd. include Punita Kumar Sinha, K B S Anand, Mark D McDade, Ramesh Swaminathan, Jean-Luc Belingard, R V Satam, Vinita Gupta, Nilesh Deshbandhu Gupta, and M D Gupta.

Who are peers of Lupin Ltd?

The peers of Lupin Ltd. include Divi's Laboratories Ltd., Gland Pharma Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Ltd., and Alkem Laboratories Ltd.

Who's the owner of Lupin?

Promoters, DII, and DII hold 47.06, 29.0, and 14.99 shares of Lupin. During the period between 30 Sep 2023 and 31 Dec 2023, the holdings have changed in the following ways: Promoter holding reduced from 47.06 to 47.04. DII holding increased from 29.0 to 29.58. FII holding increased from 14.99 to 16.11. Other investor holdings reduced from 8.95 to 7.27.

What is the 52 Week High and Low of Lupin?

The highest and lowest prices of Lupin over a period of 52 weeks are important trading indicators. Lupin showed a 52-week high of Rs 1700 and a 52-week low of Rs 628 as of 14 Feb 2024.

What is the PE and PB ratio of Lupin?

Lupin has a PE ratio of 40.9 and a PB ratio of 5.53.

What is the Share Price of Lupin?

Owing to the volatility in the arena of stocks, the share price of Lupin keeps fluctuating. As of 14 Feb 2024, Lupin's share price stands at Rs 0.00.

How to Buy Lupin Share?

If you want to purchase Lupin shares, create a demat account with IIFL. Submit proper KYC paperwork and undergo verification while making your account.

Lupin Ltd - LUPIN Share Price

Sector: Pharmaceuticals | ISIN: INE326A01037

₹ 1,594.40 (0.91%)

25 Apr, 2024, 12:00:00 AM

Trade

Expiry Date:

LUPIN - 25-04-2024

CALLS						PUTS
Total OI	Chg in Ol	Chg % Ol	LTP	Chg %	Strike Price	Chg %	LTP	Chg % OI	Chg in Ol	Total OI
5950	-1700	-22.22	233	-22.22	1,360.00	-66.67	0.05	0.0	0	16150
11900	-2550	-17.65	197.5	-17.65	1,400.00	0.00	0.05	-12.24	-5100	36550
-	-	-	-	0.00	1,420.00	100.00	0.2	-4.55	-850	17850
-	-	-	-	0.00	1,440.00	-8.33	1.65	0.0	0	2550
850	0	0.00	102	0.00	1,460.00	-50.00	0.05	0.0	0	32300
850	0	0.00	79.15	0.00	1,480.00	-50.00	0.05	-47.46	-23800	26350
2550	0	0.00	98.8	0.00	1,500.00	-85.71	0.05	-40.1	-65450	97750
2550	0	0.00	57.65	0.00	1,520.00	-93.33	0.05	-44.14	-54400	68850
20400	-8500	-29.41	59.6	-29.41	1,540.00	-96.67	0.05	-11.17	-19550	155550
28900	-11900	-29.17	32	-29.17	1,560.00	-96.92	0.2	-55.66	-146200	116450

Open
₹ 1,580.80

Prev. Close
₹ 1,580.00

Turnover(lac)
₹ 0.19

Day's High
₹ 1,600.25

Day's Low
₹ 1,578.70

52 Wk High
₹ 1,704.25

52 Wk Low
₹ 680.00

Book Value
₹ 446.60

Face Value
₹ 2.00

Mkt. Cap (Cr.)
₹ 72,664.80

P/E
34.94

EPS
45.22

Div. Yield
0.25

Lupin Ltd Corporate Actions

22 Mar , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

24 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

24 Jan , 2024

12:00 AM

Results

View Details

25 Oct , 2023

12:00 AM

Results

View Details

25 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

21 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

21 Jul , 2023

12:00 AM

Results

View Details

04 Jul , 2023

12:00 AM

AGM

Announcement date: 04 Jul , 2023

View Details

09 May , 2023

12:00 AM

Dividend

Dividend amount: 4
Announcement date: 09 May , 2023

View Details

25 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

25 Apr , 2023

12:00 AM

Results

View Details

No Record Found

Lupin Ltd News and Update

Lupin Launches Generic Mybetriq in US, Eyes Robust Sales Growth

Myrbetriq, a prescription medicine, is used to treat overactive bladder symptoms like frequent or urgent urination and urinary incontinence, including neurogenic detrusor overactivity (NDO) in children.

Lupin launches generic version of doxycycline capsules in the US

The business got Form 483 from the USFDA in March, with one observation for its Aurangabad plant, following an inspection from March 6 to March 15.

10 Apr, 2024 |
2:28 PM

Lupin names Christoph Funke as new Chief Technical Officer

He will be located in Mumbai and would be in charge of Lupin's technical operations.

19 Mar, 2024 |
11:06 AM

Lupin launches generic fertility drug Ganirelix Acetate in the US

It is the generic equivalent of Organon USA LLC's Ganirelix Acetate Injection, 250 mcg/0.5 mL, which is reference listed (RLD).

16 Feb, 2024 |
9:26 AM

Lupin Ltd FINANCIALS

No Data Available To Display Chart

Select Period:

Particulars ( Rupees In Crores.)	--	--	--	--
Gross Sales	--	--	--	--
Excise Duty	--	--	--	--
Net Sales	--	--	--	--
Other Operating Income	--	--	--	--
Other Income	--	--	--	--
Total Income	--	--	--	--
Total Expenditure **	--	--	--	--
PBIDT	--	--	--	--
Interest	--	--	--	--
PBDT	--	--	--	--
Depreciation	--	--	--	--
Minority Interest Before NP	--	--	--	--
Tax	--	--	--	--
Deferred Tax	--	--	--	--
Reported Profit After Tax	--	--	--	--
Minority Interest After NP	--	--	--	--
Net Profit after Minority Interest	--	--	--	--
Extra-ordinary Items	--	--	--	--
Adjusted Profit After Extra-ordinary item	--	--	--	--
EPS (Unit Curr.)	--	--	--	--
Book Value (Unit Curr.)	--	--	--	--
Dividend (%)	--	--	--	--
Equity	--	--	--	--
Public Shareholding (Number)	--	--	--	--
Public Shareholding (%)	--	--	--	--
Pledged/Encumbered - No. of Shares	--	--	--	--
Pledged/Encumbered - % in Total Promoters Holding	--	--	--	--
Pledged/Encumbered - % in Total Equity	--	--	--	--
Non Encumbered - No. of Shares	--	--	--	--
Non Encumbered - % in Total Promoters Holding	--	--	--	--
Non Encumbered - % in Total Equity	--	--	--	--
PBIDTM(%)	--	--	--	--
PBDTM(%)	--	--	--	--
PATM(%)	--	--	--	--

No Record Found

Particulars ( Rupees In Crores.)	--	--	--	--
Gross Sales	--	--	--	--
Excise Duty	--	--	--	--
Net Sales	--	--	--	--
Other Operating Income	--	--	--	--
Other Income	--	--	--	--
Total Income	--	--	--	--
Total Expenditure **	--	--	--	--
PBIDT	--	--	--	--
Interest	--	--	--	--
PBDT	--	--	--	--
Depreciation	--	--	--	--
Minority Interest Before NP	--	--	--	--
Tax	--	--	--	--
Deferred Tax	--	--	--	--
Reported Profit After Tax	--	--	--	--
Minority Interest After NP	--	--	--	--
Net Profit after Minority Interest	--	--	--	--
Extra-ordinary Items	--	--	--	--
Adjusted Profit After Extra-ordinary item	--	--	--	--
EPS (Unit Curr.)	--	--	--	--
Book Value (Unit Curr.)	--	--	--	--
Dividend (%)	--	--	--	--
Equity	--	--	--	--
Public Shareholding (Number)	--	--	--	--
Public Shareholding (%)	--	--	--	--
Pledged/Encumbered - No. of Shares	--	--	--	--
Pledged/Encumbered - % in Total Promoters Holding	--	--	--	--
Pledged/Encumbered - % in Total Equity	--	--	--	--
Non Encumbered - No. of Shares	--	--	--	--
Non Encumbered - % in Total Promoters Holding	--	--	--	--
Non Encumbered - % in Total Equity	--	--	--	--
PBIDTM(%)	--	--	--	--
PBDTM(%)	--	--	--	--
PATM(%)	--	--	--	--

No Record Found

Lupin Ltd PEER COMPARISON

Company Name	LTP (₹)	P/E (%)	Mkt.Cap (₹Cr.)	NP Qtr (₹Cr.)	Div.Yield (%)	Sales Qtr (₹.Cr)	Book Value (₹)
Sun Pharmaceuticals Industries Ltd	1,520.55	86.57	3,56,625.15	721.31	0.77	4,903.66	100.23
Cipla Ltd	1,405.40	34.34	1,12,938.41	1,114.14	0.61	3,798.31	320.56
Divis Laboratories Ltd	3,840.75	74.28	1,01,314.76	358.00	0.79	1,808.00	474.52
Dr Reddys Laboratories Ltd	6,217.15	24.95	99,276.89	475.20	0.67	4,083.10	1,361.85
Mankind Pharma Ltd	2,398.80	58.25	96,143.23	487.07	0.00	2,358.57	216.45

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Lupin Ltd

M D Gupta
Chairman (Non-Executive)

Nilesh Deshbandhu Gupta.
Managing Director

Vinita Gupta
Director & Chief Executive Off

R V Satam
Company Sec. & Compli. Officer

Jean-Luc Belingard
Independent Director

Ramesh Swaminathan
Executive Director & CFO

Mark D McDade
Independent Director

K B S Anand
Independent Director

Punita Kumar Sinha
Independent Director

Summary

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments.Lupin Ltd was incorporated in the year 1983 with the name Lupin Chemicals Ltd. In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar. In the year 1989, the company established a joint venture in Thailand, namely Lupin Chemicals (Thailand) Ltd. In the year 1991, they initiated production of Injectable cephalosporin (bulk and dosages) at Mandideep. In the year 1992, the company set up Fermentation Plant at Tarapur, Maharashtra. Also, Sterile Plant for injectable Cephalosporins (bulk) was commissioned at Mandideep.In the year 2001, Lupin Laboratories Ltd was amalgamated with the company and the name was changed to Lupin Ltd. They commenced supply of Cephalosporin bulk actives to their alliance partners in the US. Also, they commissioned a state of the art US FDA approvable oral cephalosporin bulk active plant. In the year 2002, the company commissioned the new Anti-TB facility at Aurangabad. In the year 2003,... Read More

Reports by Lupin Ltd
Annual ReportAuditors Report
Management DiscussionDirectors Report

Reports by Lupin Ltd
Investor PresentationConference Call TranscriptConference Call Audio

Company FAQ

What is the Market Cap of Lupin?
It indicates the value of the outstanding shares of a publicly traded firm. As of 25 Apr, 2024, Lupin's market cap stands at Rs 72664.80 crores.
Is Lupin part of Nifty 50?
Yes, Lupin belongs to the Nifty 50 index.
What is the dividend of Lupin in 2023?
In March 2023, Lupin declared an equity dividend of 200% with Rs 4 per share. The company's current share price provided a 0.25% dividend yield.
Is Lupin a debt-free company?
Lupin can be virtually considered debt-free, with a PEG ratio of 0.22 and a smooth conversion cycle of 65.84 days.
Is Lupin a good stock to buy?
Lupin seems like a good stock to buy on the basis of its current market price, future growth prospects, and profit margins. Moreover, the company has no threat of bankruptcy in the near future.
What is the future of Lupin Limited's shares?
Lupin Limited's shares are going to increase in value in the future as the company is focusing on enhanced patient care and drug development to generate fresh revenue streams.
What is Lupin Ltd Share symbol?
Lupin Ltd. has a share symbol of LUPIN.
Who is/are the promoter/promoters of Lupin Ltd?
The promoters of Lupin Ltd. include Punita Kumar Sinha, K B S Anand, Mark D McDade, Ramesh Swaminathan, Jean-Luc Belingard, R V Satam, Vinita Gupta, Nilesh Deshbandhu Gupta, and M D Gupta.
Who are peers of Lupin Ltd?
The peers of Lupin Ltd. include Divi's Laboratories Ltd., Gland Pharma Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Ltd., and Alkem Laboratories Ltd.
Who's the owner of Lupin?
Promoters, DII, and DII hold 47.06, 29.0, and 14.99 shares of Lupin. During the period between 30 Sep 2023 and 31 Dec 2023, the holdings have changed in the following ways: Promoter holding reduced from 47.06 to 47.04. DII holding increased from 29.0 to 29.58. FII holding increased from 14.99 to 16.11. Other investor holdings reduced from 8.95 to 7.27.
What is the 52 Week High and Low of Lupin?
The highest and lowest prices of Lupin over a period of 52 weeks are important trading indicators. Lupin showed a 52-week high of Rs 1700 and a 52-week low of Rs 628 as of 14 Feb 2024.
What is the PE and PB ratio of Lupin?
Lupin has a PE ratio of 40.9 and a PB ratio of 5.53.
What is the Share Price of Lupin?
Owing to the volatility in the arena of stocks, the share price of Lupin keeps fluctuating. As of 14 Feb 2024, Lupin's share price stands at Rs 0.00.
How to Buy Lupin Share?
If you want to purchase Lupin shares, create a demat account with IIFL. Submit proper KYC paperwork and undergo verification while making your account.

ATTENTION INVESTORS

Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

Risk Disclosure on Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to Rs. 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.

ATTENTION INVESTORS

Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

Risk Disclosure on Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to Rs. 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.